Back to search results

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Abroad (travel likely)RecruitingPHASE3

Conditions

Atypical Hemolytic Uremic Syndrome

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Novartis Investigative Site, Nanjing, Jiangsu, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Bordeaux, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Rouen, France

  • Novartis Investigative Site, Toulouse, France

  • Novartis Investigative Site, Tours, France

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, Kiel, Germany

  • Novartis Investigative Site, Ranica, BG, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Matsumoto-shi, Nagano, Japan

  • Novartis Investigative Site, Iruma-gun, Saitama, Japan

  • Novartis Investigative Site, Bunkyo Ku, Tokyo, Japan

  • Novartis Investigative Site, Santiago Compostela, A Coruna, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Córdoba, Spain

  • Novartis Investigative Site, Málaga, Spain

  • Novartis Investigative Site, Seville, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Izmir, Balcova, Turkey (Türkiye)

  • Novartis Investigative Site, Köseköy, Kocaeli, Turkey (Türkiye)

  • Novartis Investigative Site, Ankara, Yenimahalle, Turkey (Türkiye)

  • Novartis Investigative Site, Mersin, Yenisehir, Turkey (Türkiye)

  • Novartis Investigative Site, Glasgow, Scotland, United Kingdom

  • Novartis Investigative Site, Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

Study leads

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)